Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T15803
(Former ID: TTDC00330)
|
|||||
| Target Name |
Factor XI messenger RNA (F11 mRNA)
|
|||||
| Synonyms |
Plasma thromboplastin antecedent (mRNA); PTA (mRNA); FXI (mRNA); Coagulation factor XI (mRNA)
Click to Show/Hide
|
|||||
| Gene Name |
F11
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 4 Target-related Diseases | + | ||||
| 1 | Cerebral ischaemic stroke [ICD-11: 8B11] | |||||
| 2 | Coagulation defect [ICD-11: 3B10] | |||||
| 3 | Thrombosis [ICD-11: DB61-GB90] | |||||
| 4 | Alzheimer disease [ICD-11: 8A20] | |||||
| Function |
Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
Click to Show/Hide
|
|||||
| BioChemical Class |
mRNA target
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 3.4.21.27
|
|||||
| Sequence |
MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFT
FTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDM KGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITK LDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFT FFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTD FLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKIL HGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSI IGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYD IALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLV TNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCA QRERPGVYTNVVEYVDWILEKTQAV Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | BMS-986177 | Drug Info | Phase 2 | Cerebral ischemia | [2] | |
| 2 | IONIS-416858 | Drug Info | Phase 2 | Thrombosis | [3] | |
| 3 | ISIS-FXI | Drug Info | Phase 2 | Coagulation defect | [4] | |
| 4 | alpha-ketothiazole analogue 36 | Drug Info | Clinical trial | Alzheimer disease | [5] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 3 Inhibitor drugs | + | ||||
| 1 | BMS-986177 | Drug Info | [6] | |||
| 2 | IONIS-416858 | Drug Info | [3] | |||
| 3 | alpha-ketothiazole analogue 36 | Drug Info | [7] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 1 KEGG Pathways | + | ||||
| 1 | Complement and coagulation cascades | |||||
| Pathwhiz Pathway | [+] 1 Pathwhiz Pathways | + | ||||
| 1 | Coagulation | |||||
| Reactome | [+] 1 Reactome Pathways | + | ||||
| 1 | Intrinsic Pathway of Fibrin Clot Formation | |||||
| WikiPathways | [+] 3 WikiPathways | + | ||||
| 1 | Human Complement System | |||||
| 2 | Blood Clotting Cascade | |||||
| 3 | Formation of Fibrin Clot (Clotting Cascade) | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||||
| REF 2 | ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health. | |||||
| REF 3 | Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. | |||||
| REF 4 | ClinicalTrials.gov (NCT01713361) Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty. U.S. National Institutes of Health. | |||||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6549). | |||||
| REF 6 | Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195-1205. | |||||
| REF 7 | Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. | |||||
| REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2360). | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.